Extrapolations of Periwinkle Secondary Metabolites as Multitarget Inhibitor of Breast Cancer Proteins

Year : 2023 | Volume : 01 | Issue : 01 | Page : 36 49
    By

    Aparna Prasad,

  1. Student, Department of Biotechnology, Pillai College of Arts, Commerce & Science (Autonomous) (affiliated to Mumbai University), New Panvel, Mumbai, Maharashtra, India

Abstract

Objective: Breast cancer is considered one of the most common and dangerous forms of cancer. It is a significant public health issue on a global scale. The study estimates that 10.0 million people will die from cancer this year, and 19.3 million people will develop the disease overall (BC). In this computation approach, nowadays emphasizes new drug discovery, the target protein epidermal growth factor receptor (EGFR) (5UGB), estrogen receptor (ER) (2QGT), and PI3KA (4OYS) were chosen to perform molecular docking against the derivatives of periwinkle Catharanthus phytochemical and FDA-approved drugs. Its pharmacological characteristics and its therapeutic analysis were investigated. Methods: The study was based on a computational approach using different phytocompounds for evaluation of their inhibitory potential against the target proteins EGFR, ER, and PI3KA. The protein molecular docking was conducted systematically using IMPPAT, PubChem, PDB, Open Bable, BIOVIA Discovery Studio Visualizer, PDB sum generate, PyRx, and ADMETlab 2.0. Result: The docking result revealed that the ligands selected have the best binding affinity with all three target proteins. Conclusion: The ligands could potentially be used to treat breast cancer in future approaches for studying the urge ligands in vitro and in vivo analysis to create novel breast cancer inhibitors.

Keywords: Breast cancer, Catharanthus, periwinkle, EGFR, ER, PI3KA, vindolininol, lochnericine, lochnerinine, molecular docking, ADMET

[This article belongs to International Journal of Biochemistry and Biomolecule Research ]

How to cite this article:
Aparna Prasad. Extrapolations of Periwinkle Secondary Metabolites as Multitarget Inhibitor of Breast Cancer Proteins. International Journal of Biochemistry and Biomolecule Research. 2023; 01(01):36-49.
How to cite this URL:
Aparna Prasad. Extrapolations of Periwinkle Secondary Metabolites as Multitarget Inhibitor of Breast Cancer Proteins. International Journal of Biochemistry and Biomolecule Research. 2023; 01(01):36-49. Available from: https://journals.stmjournals.com/ijbbr/article=2023/view=128271


Browse Figures

References

1. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109–26.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660.
3. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109–26.
4. Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474–82. doi: 10.1097/01.SLA.0000059969.64262.87.
5. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151–64. doi: 10.2147/BCTT.S176070.
6. Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609–23.
7. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, et al. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol. 2010, December;21(9):951–60. doi: 10.1016/j.semcdb.2010.08.009.
8. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012;14(3):R72. doi: 10.1186/bcr3181.
9. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003;9(7):2406–15.
10. Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Daneshmand M, et al. Abstract C1: BRCA1 protein levels and PI3KA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: an exploratory analysis. Mol Cancer Ther. 2011;10(11_Supplement):C1-:Abstract C1:. doi: 10.1158/1535–7163.TARG-11-C1.
11. Gawade M, Zaware DM, Gaikwad C, Kumbhar R, Chavan T. Catharanthus roseus L. (Periwinkle): an herb with impressive health benefits and pharmacological therapeutic effects. Int J Agric Nutr. 2022;4(2):52–7. doi: 10.33545/26646064.2022.v4.i2a.81.
12. Dada WP, Nilima W. Vinca rosea: as a potent anticancer. Ann Genet. 2021.
13. Das S, Sharangi AB. Madagascar periwinkle (Catharanthus roseus L.): diverse medicinal and therapeutic benefits to humankind. J Pharmacogn Phytochem. 2017;6(5):1695–701.
14. Ahmed B, Ashfaq UA, ul Qamar MT, Ahmad M. Anticancer potential of phytochemicals against breast cancer: molecular docking and simulation approach. Bangladesh J Pharmacol. 2014;9(4):545–50.
15. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41. doi: 10.3322/caac.21754.
16. Acharya R, Chacko S, Bose P, Lapenna A, Pattanayak SP. Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci Rep. 2019;9(1):15743. doi: 10.1038/s41598–019–52162–0.
17. Yang Y, Tao R, Shu X, Cai Q, Wen W, Gu K et al. Incorporating polygenic risk scores and nongenetic risk factors for breast cancer risk prediction among Asian women. JAMA Netw Open. 2022;5(3):e2149030. doi: 10.1001/jamanetworkopen.2021.49030.
18. Hossein-Nejad-Ariani H, Althagafi E, Kaur K. Small peptide ligands for targeting EGFR in triple negative breast cancer cells. Sci Rep. 2019;9(1):2723. doi: 10.1038/s41598–019–38574-y.
19. Williams SD, Smith TM, Stewart LV, Sakwe AM. Hypoxia-inducible expression of annexin A6 enhances the resistance of triple-negative breast cancer cells to EGFR and AR antagonists. Cells. 2022;11(19):3007. doi: 10.3390/cells11193007.
20. Ma S, Tang T, Probst G, Konradi A, Jin C, Li F et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022;13(1):1061. doi: 10.1038/s41467–022–28691–0.
21. Akinnusi PA, Olubode SO, Adebesin AO, Nana TA, Shodehinde SA. Discovery of promising inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor Receptor 2 (HER2), estrogen receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for personalized breast cancer treatment. Cancer Inform. 2022;21:11769351221127862. doi: 10.1177/11769351221127862.
22. Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;25(4):392–401. doi: 10.1007/s12282–017–0812-x.
23. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five‐day continuous‐infusion vinblastine in the treatment of breast cancer. Cancer. 1985;56(2):225–9. doi: 10.1002/1097–0142(19850715)56:23.0.co;2-y.
24. Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Breast Cancer Res. 2020;22(1):33. doi: 10.1186/s13058–020–01271–0.
25. Sathiya S, Karthikeyan B, Jaleel CA, Azooz MM, Iqbal M. Antibiogram of Catharanthus roseus extracts. Glob J Mol Sci. 2008;3(1):1–7.
26. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17(5):1413. doi: 10.1200/JCO.1999.17.5.1413.
27. Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q et al. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2018;24(13):2999–3004. doi: 10.1158/1078–0432.CCR-17–2369.

Regular Issue Subscription Original Research
Volume 01
Issue 01
Received 13/04/2023
Accepted 17/04/2023
Published 05/05/2023
Publication Time 22 Days
402

Login


My IP

PlumX Metrics